(Q24629295)

English

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

scientific article

In more languages

Statements

scholarly article

0 references

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial (English)

0 references

phase II clinical trial

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Pauline Wimberger

13

object named as

Pauline Wimberger

0 references

Barbara Schmalfeldt

15

object named as

Barbara Schmalfeldt

0 references

Carsten Bokemeyer

17

object named as

Carsten Bokemeyer

0 references

author name string

Markus M Heiss

1

0 references

Pawel Murawa

2

0 references

Piotr Koralewski

3

0 references

Elzbieta Kutarska

4

0 references

Olena O Kolesnik

5

0 references

Vladimir V Ivanchenko

6

0 references

Alexander S Dudnichenko

7

0 references

Birute Aleknaviciene

8

0 references

Arturas Razbadauskas

9

0 references

Martin Gore

10

0 references

Elena Ganea-Motan

11

0 references

Tudor Ciuleanu

12

0 references

Alexander Schmittel

14

0 references

Alexander Burges

16

0 references

Horst Lindhofer

18

0 references

Angelika Lahr

19

0 references

Simon L Parsons

20

0 references

language of work or name

0 references

publication date

1 November 2010

0 references

International Journal of Cancer

0 references

127

0 references

2209-21

0 references

9

0 references

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

7 April 2017

Frequent EpCam protein expression in human carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

7 April 2017

The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The pathogenesis of malignant ascites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Malignant ascites: systematic review and guideline for treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Immunotherapy of malignant ascites with trifunctional antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Characterization of human IgG antimouse antibody in patients with B-cell malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The current and future management of malignant ascites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

The past, the present and future of the OK-432 therapy for patients with malignant effusions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Malignant ascites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

New strategies for the management of malignant ascites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

General aspects of cytokine-release syndrome: timing and incidence of symptoms.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Intraperitoneal interferon in the management of malignant ascites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

Malignant ascites. Clinical and experimental observations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

27 September 2017

CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

30 May 2018

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958458

28 November 2018

The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Utility of BER-EP4 in the diagnosis of adenocarcinoma in effusions: an immunocytochemical study of 232 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A survey of practice in management of malignant ascites

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20473913

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/IJC.25423

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24629295&oldid=1406033199"